Cargando…

TFAM is a novel mediator of immunogenic cancer cell death

Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic can...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Minghua, Li, Changfeng, Zhu, Shan, Cao, Lizhi, Kroemer, Guido, Zeh, Herbert, Tang, Daolin, Kang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980348/
https://www.ncbi.nlm.nih.gov/pubmed/29872558
http://dx.doi.org/10.1080/2162402X.2018.1431086
_version_ 1783327870611881984
author Yang, Minghua
Li, Changfeng
Zhu, Shan
Cao, Lizhi
Kroemer, Guido
Zeh, Herbert
Tang, Daolin
Kang, Rui
author_facet Yang, Minghua
Li, Changfeng
Zhu, Shan
Cao, Lizhi
Kroemer, Guido
Zeh, Herbert
Tang, Daolin
Kang, Rui
author_sort Yang, Minghua
collection PubMed
description Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion.
format Online
Article
Text
id pubmed-5980348
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-59803482018-06-05 TFAM is a novel mediator of immunogenic cancer cell death Yang, Minghua Li, Changfeng Zhu, Shan Cao, Lizhi Kroemer, Guido Zeh, Herbert Tang, Daolin Kang, Rui Oncoimmunology Original Research Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion. Taylor & Francis 2018-02-15 /pmc/articles/PMC5980348/ /pubmed/29872558 http://dx.doi.org/10.1080/2162402X.2018.1431086 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Original Research
Yang, Minghua
Li, Changfeng
Zhu, Shan
Cao, Lizhi
Kroemer, Guido
Zeh, Herbert
Tang, Daolin
Kang, Rui
TFAM is a novel mediator of immunogenic cancer cell death
title TFAM is a novel mediator of immunogenic cancer cell death
title_full TFAM is a novel mediator of immunogenic cancer cell death
title_fullStr TFAM is a novel mediator of immunogenic cancer cell death
title_full_unstemmed TFAM is a novel mediator of immunogenic cancer cell death
title_short TFAM is a novel mediator of immunogenic cancer cell death
title_sort tfam is a novel mediator of immunogenic cancer cell death
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980348/
https://www.ncbi.nlm.nih.gov/pubmed/29872558
http://dx.doi.org/10.1080/2162402X.2018.1431086
work_keys_str_mv AT yangminghua tfamisanovelmediatorofimmunogeniccancercelldeath
AT lichangfeng tfamisanovelmediatorofimmunogeniccancercelldeath
AT zhushan tfamisanovelmediatorofimmunogeniccancercelldeath
AT caolizhi tfamisanovelmediatorofimmunogeniccancercelldeath
AT kroemerguido tfamisanovelmediatorofimmunogeniccancercelldeath
AT zehherbert tfamisanovelmediatorofimmunogeniccancercelldeath
AT tangdaolin tfamisanovelmediatorofimmunogeniccancercelldeath
AT kangrui tfamisanovelmediatorofimmunogeniccancercelldeath